Oncology Ebit vs Net Income From Continuing Ops Analysis

TOI Stock

USD 0.15 0.01 6.25%

Oncology Institute financial indicator trend analysis is much more than just breaking down Oncology Institute prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Oncology Institute is a good investment. Please check the relationship between Oncology Institute Ebit and its Net Income From Continuing Ops accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Oncology Institute. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.

Ebit vs Net Income From Continuing Ops

Ebit vs Net Income From Continuing Ops Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Oncology Institute Ebit account and Net Income From Continuing Ops. At this time, the significance of the direction appears to have totally related.

The correlation between Oncology Institute's Ebit and Net Income From Continuing Ops is 1.0. Overlapping area represents the amount of variation of Ebit that can explain the historical movement of Net Income From Continuing Ops in the same time period over historical financial statements of Oncology Institute, assuming nothing else is changed. The correlation between historical values of Oncology Institute's Ebit and Net Income From Continuing Ops is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit of Oncology Institute are associated (or correlated) with its Net Income From Continuing Ops. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income From Continuing Ops has no effect on the direction of Ebit i.e., Oncology Institute's Ebit and Net Income From Continuing Ops go up and down completely randomly.

Correlation Coefficient

1.0

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Ebit

Net Income From Continuing Ops

Most indicators from Oncology Institute's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Oncology Institute current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Oncology Institute. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.The Oncology Institute's current Selling General Administrative is estimated to increase to about 121.1 M, while Tax Provision is forecasted to increase to (84.5 K).

	2021	2022	2023	2024 (projected)
Interest Expense	320K	4.1M	6.8M	7.1M
Depreciation And Amortization	3.3M	4.4M	5.9M	3.8M

Interest Expense Depreciation And Amortization

Oncology Institute fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Good Will	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets
Common Stock Shares Outstanding		0.84	0.85	0.88	0.68	0.33	0.7	0.74	0.4	-0.78	0.69	0.53	0.7	0.8	0.82	0.79	0.8	0.31	0.83	0.76	0.78	0.89	0.86	0.78	0.72	0.82
Total Assets	0.84		0.98	0.86	0.9	0.45	0.89	0.82	0.4	-0.78	0.65	0.64	0.86	0.91	0.95	0.94	0.91	0.45	0.98	0.86	0.91	0.96	0.97	0.98	0.79	0.97
Other Current Liab	0.85	0.98		0.92	0.84	0.53	0.92	0.8	0.33	-0.85	0.78	0.73	0.75	0.94	0.95	0.97	0.89	0.4	0.97	0.88	0.96	0.98	0.98	0.94	0.79	0.99
Total Current Liabilities	0.88	0.86	0.92		0.63	0.4	0.75	0.78	0.38	-0.91	0.87	0.63	0.63	0.89	0.87	0.86	0.84	0.23	0.88	0.85	0.87	0.97	0.92	0.77	0.78	0.89
Total Stockholder Equity	0.68	0.9	0.84	0.63		0.56	0.85	0.59	0.18	-0.5	0.43	0.64	0.85	0.66	0.74	0.84	0.68	0.75	0.79	0.57	0.81	0.77	0.78	0.89	0.55	0.84
Other Liab	0.33	0.45	0.53	0.4	0.56		0.75	-0.02	-0.62	-0.22	0.64	0.95	0.06	0.34	0.32	0.7	0.11	0.71	0.35	0.17	0.74	0.46	0.36	0.36	-0.03	0.6
Net Tangible Assets	0.7	0.89	0.92	0.75	0.85	0.75		0.63	0.04	-0.71	0.77	0.89	0.57	0.82	0.8	0.98	0.68	0.52	0.84	0.71	0.97	0.85	0.84	0.84	0.62	0.95
Property Plant And Equipment Net	0.74	0.82	0.8	0.78	0.59	-0.02	0.63		0.79	-0.9	0.53	0.29	0.76	0.87	0.85	0.68	0.93	-0.07	0.88	0.91	0.64	0.82	0.88	0.83	1.0	0.76
Net Debt	0.4	0.4	0.33	0.38	0.18	-0.62	0.04	0.79		-0.55	0.0	-0.36	0.63	0.48	0.5	0.12	0.69	-0.41	0.5	0.61	0.06	0.38	0.49	0.47	0.79	0.25
Retained Earnings	-0.78	-0.78	-0.85	-0.91	-0.5	-0.22	-0.71	-0.9	-0.55		-0.83	-0.52	-0.54	-0.9	-0.83	-0.77	-0.85	0.06	-0.85	-0.9	-0.77	-0.88	-0.87	-0.72	-0.92	-0.82
Accounts Payable	0.69	0.65	0.78	0.87	0.43	0.64	0.77	0.53	0.0	-0.83		0.83	0.22	0.74	0.65	0.82	0.55	0.19	0.67	0.66	0.86	0.81	0.71	0.52	0.55	0.8
Cash	0.53	0.64	0.73	0.63	0.64	0.95	0.89	0.29	-0.36	-0.52	0.83		0.21	0.58	0.53	0.86	0.35	0.59	0.57	0.43	0.89	0.67	0.59	0.54	0.28	0.79
Non Current Assets Total	0.7	0.86	0.75	0.63	0.85	0.06	0.57	0.76	0.63	-0.54	0.22	0.21		0.68	0.79	0.63	0.84	0.42	0.81	0.68	0.58	0.74	0.8	0.9	0.71	0.7
Non Currrent Assets Other	0.8	0.91	0.94	0.89	0.66	0.34	0.82	0.87	0.48	-0.9	0.74	0.58	0.68		0.98	0.89	0.95	0.1	0.98	0.98	0.86	0.94	0.98	0.9	0.87	0.94
Other Assets	0.82	0.95	0.95	0.87	0.74	0.32	0.8	0.85	0.5	-0.83	0.65	0.53	0.79	0.98		0.88	0.97	0.2	0.99	0.96	0.84	0.95	0.99	0.95	0.83	0.93
Cash And Short Term Investments	0.79	0.94	0.97	0.86	0.84	0.7	0.98	0.68	0.12	-0.77	0.82	0.86	0.63	0.89	0.88		0.77	0.49	0.91	0.79	0.99	0.93	0.91	0.88	0.66	0.99
Net Receivables	0.8	0.91	0.89	0.84	0.68	0.11	0.68	0.93	0.69	-0.85	0.55	0.35	0.84	0.95	0.97	0.77		0.08	0.97	0.97	0.73	0.91	0.96	0.93	0.91	0.85
Good Will	0.31	0.45	0.4	0.23	0.75	0.71	0.52	-0.07	-0.41	0.06	0.19	0.59	0.42	0.1	0.2	0.49	0.08		0.25	-0.05	0.51	0.33	0.25	0.4	-0.12	0.42
Non Current Liabilities Total	0.83	0.98	0.97	0.88	0.79	0.35	0.84	0.88	0.5	-0.85	0.67	0.57	0.81	0.98	0.99	0.91	0.97	0.25		0.95	0.87	0.96	1.0	0.97	0.86	0.95
Inventory	0.76	0.86	0.88	0.85	0.57	0.17	0.71	0.91	0.61	-0.9	0.66	0.43	0.68	0.98	0.96	0.79	0.97	-0.05	0.95		0.76	0.9	0.95	0.87	0.9	0.86
Other Current Assets	0.78	0.91	0.96	0.87	0.81	0.74	0.97	0.64	0.06	-0.77	0.86	0.89	0.58	0.86	0.84	0.99	0.73	0.51	0.87	0.76		0.93	0.89	0.83	0.63	0.98
Other Stockholder Equity	0.89	0.96	0.98	0.97	0.77	0.46	0.85	0.82	0.38	-0.88	0.81	0.67	0.74	0.94	0.95	0.93	0.91	0.33	0.96	0.9	0.93		0.98	0.9	0.8	0.96
Total Liab	0.86	0.97	0.98	0.92	0.78	0.36	0.84	0.88	0.49	-0.87	0.71	0.59	0.8	0.98	0.99	0.91	0.96	0.25	1.0	0.95	0.89	0.98		0.95	0.86	0.96
Net Invested Capital	0.78	0.98	0.94	0.77	0.89	0.36	0.84	0.83	0.47	-0.72	0.52	0.54	0.9	0.9	0.95	0.88	0.93	0.4	0.97	0.87	0.83	0.9	0.95		0.79	0.92
Property Plant And Equipment Gross	0.72	0.79	0.79	0.78	0.55	-0.03	0.62	1.0	0.79	-0.92	0.55	0.28	0.71	0.87	0.83	0.66	0.91	-0.12	0.86	0.9	0.63	0.8	0.86	0.79		0.74
Total Current Assets	0.82	0.97	0.99	0.89	0.84	0.6	0.95	0.76	0.25	-0.82	0.8	0.79	0.7	0.94	0.93	0.99	0.85	0.42	0.95	0.86	0.98	0.96	0.96	0.92	0.74

Click cells to compare fundamentals

Oncology Institute Account Relationship Matchups

Oncology Institute fundamental ratios Accounts

		2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding		64.4M	59.1M	66.2M	80.6M	73.7M	68.4M

Currently Active Assets on Macroaxis

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America
S	SentinelOne
WD	Walker Dunlop

When determining whether Oncology Institute offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oncology Institute's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oncology Institute Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oncology Institute Stock:

How To Invest In Oncology

Details

Is Oncology Stock a good investment?

Details

What is Oncology Institute's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Oncology Institute. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.

You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncology Institute. If investors know Oncology will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncology Institute listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.77)

Revenue Per Share

4.873

Quarterly Revenue Growth

0.229

Return On Assets

(0.19)

Return On Equity

(1.26)

The market value of Oncology Institute is measured differently than its book value, which is the value of Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Oncology Institute's value that differs from its market value or its book value, called intrinsic value, which is Oncology Institute's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncology Institute's market value can be influenced by many factors that don't directly affect Oncology Institute's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Oncology Institute's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncology Institute is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncology Institute's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Oncology Ebit vs Net Income From Continuing Ops Analysis

Ebit vs Net Income From Continuing Ops

Ebit vs Net Income From Continuing Ops Correlation Analysis

Correlation Coefficient

Ebit

Net Income From Continuing Ops

Oncology Institute fundamental ratios Correlations

Oncology Institute Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Oncology Institute fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Liab	+ 1.0	Non Current Liabilities Total
Total Current Assets	+ 0.99	Other Current Liab
Non Current Liabilities Total	+ 0.99	Other Assets
Total Liab	+ 0.99	Other Assets
Other Current Assets	+ 0.99	Cash And Short Term Investments

Property Plant And Equipment Gross	- 0.92	Retained Earnings
Retained Earnings	- 0.91	Total Current Liabilities
Inventory	- 0.9	Retained Earnings
Non Currrent Assets Other	- 0.9	Retained Earnings
Retained Earnings	- 0.9	Property Plant And Equipment Net
Other Stockholder Equity	- 0.88	Retained Earnings